Health tech companies zeroing in on metabolic health advancements continue to score investors as they look to make it easier than ever for consumers to assess metabolic insights.
Biolinq, a wearable biosensor maker, just closed a $58 million financing round that will support its clinical trial this year and could propel its intradermal glucose sensor closer to eventual FDA approval. For now, Biolinq’s continuous glucose sensor is purely in investigational device mode and hasn’t yet been cleared or approved by the FDA.
The San Diego-based health tech startup has developed an impressive wearable device for the upper arm, which uses tiny electrochemical sensors to measure glucose levels just beneath the skin’s surface, which Biolinq says is 20 times more shallow than traditional glucose monitors.
While other biosensor wearables require a secondary device to review a reading, a simple glance at Biolinq’s futuristic-looking interface can reveal real-time glucose insights based on its color.
Read more at: https://athletechnews.com/biolinq-raises-58m-for-color-coded-wearable-glucose-sensor/
